Rhythm Pharmaceuticals Stock
Price
Target price
€85.50
€85.50
-1.160%
-1.0
-1.160%
€93.84
08.01.26 / Stuttgart Stock Exchange
WKN: A2H5A0 / Symbol: RYTM / Name: Rhythm Pharmaceuticals / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Rhythm Pharmaceuticals Stock
A loss of -1.160% shows a downward development for Rhythm Pharmaceuticals.
The stock is an absolute favorite of our community with 38 Buy predictions and no Sell predictions.
With a target price of 93 € there is a slightly positive potential of 8.77% for Rhythm Pharmaceuticals compared to the current price of 85.5 €.
Our community identified positive and negative aspects for Rhythm Pharmaceuticals stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Rhythm Pharmaceuticals stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Rhythm Pharmaceuticals in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Rhythm Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals | -1.160% | -8.556% | -2.841% | 50.079% | -8.556% | 186.913% | 214.338% |
| Ardelyx Inc. | 20.070% | 22.231% | 18.703% | 16.087% | 22.231% | 122.288% | 11.765% |
| Evolus Inc | 0.000% | -13.394% | -17.193% | -52.800% | -13.394% | -35.782% | 53.947% |
| Champions Oncology Inc | -0.910% | -6.034% | 9.000% | 14.496% | -6.034% | 36.250% | -39.444% |
Comments
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at HC Wainwright from $110.00 to $123.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RYTM provided by MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Show more
Ratings data for RYTM provided by MarketBeat
News
Rhythm Stock: Obesity Drug Spurs Analyst Optimism
Rhythm Pharmaceuticals has captured Wall Street's attention following impressive Phase 2 results for its experimental obesity medication, Bivamelagon. The biotech company's shares surged 10% after
